LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ultra-Performance LC-MS System Approved for Clinical Applications in China

By LabMedica International staff writers
Posted on 03 Jul 2014
Print article
Waters Co.\'s ACQUITY UPLC TQD
Liquid chromatography – mass spectrometry system (Photo courtesy of WATERS CORPORATION)
An ultra-performance liquid chromatography – mass spectrometry (UPLC-MS) system has been approved by the Chinese Food and Drug Administration (CFDA) as a medical device for routine diagnostic applications and for screening of neonatal metabolites diseases.

The CFDA approval was granted for the ACQUITY UPLC TQD from Waters Corporation (Milford, MA, USA). A continuation of Waters' commitment to China and to growing clinical LC-MS applications worldwide, this represents the second Waters' mass spectrometer approved for in vitro diagnostic (IVD) applications in China (in 2008, the CFDA (formerly SFDA) approved a neonatal screening solution inclusive of the Waters Quattro micro mass spectrometer).

An UPLC tandem quadrupole mass spectrometry (UPLC/MS/MS) system, the ACQUITY UPLC TQD (tandem quadrupole detector) is a benchtop, ultra-compact, tandem-quadrupole, mass detector-based system designed for routine UPLC/MS/MS analyses and quantitative applications, featuring high levels of MS selectivity, robustness, speed, and accuracy. To maximize the analytical advantages of UPLC, the ACQUITY TQD operates at the highest data acquisition rates. Integrated with the Waters ACQUITY UPLC System, the ACQUITY TQD gives class-leading analytical detection limits, resolution, and sample throughput.

"The approval by the CFDA of ACQUITY UPLC MS/MS system as a medical device is significant for two reasons. First and most importantly, this registration opens the door for millions of Chinese citizens to benefit from the gold standard of LC-MS diagnostic analysis," said Dr. Rohit Khanna, vice president of Worldwide Marketing and Informatics at Waters, "Secondly, this commitment to China's analytical scientists and laboratories reinforces Waters' strategy of expanding applications of our core chromatography and mass spectrometry technologies throughout the world. As of this decision by the CFDA, the ACQUITY UPLC, MS/MS system is registered as a medical device in 29 countries plus the European Economic Area, which includes an additional 30 countries."

Related Links:

Waters Corporation
ACQUITY UPLC TQD


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more